Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A Nerve Agent Antidote That Could Be Taken Before An Attack

By American Chemical Society | October 10, 2016

Nerve agents are molecular weapons that invade the body and sabotage part of the nervous system, causing horrific symptoms and sometimes death within minutes. Few antidotes exist, and those that do must be administered soon after an attack. But now scientists report in the journal ACS Nano an early-stage development of a potential treatment that soldiers or others could take before such agents are unleashed.

One particular antidote, an enzyme called organophosphorus acid anhydrolase (OPAA), has attracted attention recently for its ability to break down nerve agents. But the body’s immune system gets rid of it quickly. Packaging the enzyme in liposome nanocarriers gives the antidote greater staying power, but handling and storing the liposomes is complicated. So Omar K. Farha and colleagues wanted to make a potentially simpler carrier.

For a material, the researchers turned to porous metal-organic frameworks (MOFs), a class of hybrid materials made of metallic ions and organic ligands that are easy to store and handle at room temperature. They used a zirconium-based MOF and loaded it with the antidote. Testing showed the MOF-encapsulated enzyme was even more effective at breaking down the nerve agent simulant diisopropyl fluorophosphate and the nerve agent soman than the antidote by itself.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE